News
SLP
45.03
+0.07%
0.03
Weekly Report: what happened at SLP last week (0415-0419)?
Weekly Report · 1d ago
Simulations Plus (NASDAQ:SLP): Promising Potential in Biotech Software
TipRanks · 04/16 09:48
Weekly Report: what happened at SLP last week (0408-0412)?
Weekly Report · 04/15 09:20
YieldBoost Simulations Plus From 0.5% To 16.1% Using Options
NASDAQ · 04/09 15:35
Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA
NASDAQ · 04/08 13:06
Weekly Report: what happened at SLP last week (0401-0405)?
Weekly Report · 04/08 09:21
Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket
Reliance Global Group, Inc. Shares fell sharply in today’s pre-market trading after reporting financial results for the year ended Dec 31, 2023. The company posted a net loss of $12.0 million for 2023, compared to net income of $6.5 million in 2022. Gainers MediaCo Holding Inc. Rose 175% to $3.85 in pre- market trading.
Benzinga · 04/05 09:45
Health Care Sector Update for 04/04/2024: FNA, SLP, ADCT, ALUR
NASDAQ · 04/04 20:03
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. The company issued strong preliminary first-quarter net sales guidance. TC Biopharm (Holdings) Plc shares climbed 130.1% in the mid-day session.
Benzinga · 04/04 17:21
Simulations Plus stock jumps 25% amid FDA renewal, earnings report
Simulations Plus stock jumps 25% amid FDA renewal, earnings report. The company announced the FDA had renewed its license to the DILIsym toxicology software platform for the seventh year. Simulations Plus reported fiscal Q2 revenue rose 18% year-over-year to $18.3M.
Seeking Alpha · 04/04 16:19
Simulations Plus Shares Rise 27% Following FDA's License Renewal for Dilisym Software Platform
Shares of Simulations Plus are up 27% at $48.72. The company says the licenses to its Dilisym software platform have been renewed by the FDA. The stock is up about 6% for the year to date. The software predicts the potential for drug-induced liver injury.
Dow Jones · 04/04 15:52
Technology Sector Update for 04/04/2024: XLK, XSD, SLP, META, AAPL
NASDAQ · 04/04 12:47
Simulations Plus Announces U.S. FDA Renews DILIsym Software Licenses For 7th Year
The U.S. FDA has renewed its licenses to the DILIsym software platform. The software is designed for the prediction and investigation of drug-induced liver injury. The one-year renewal provides the FDA with continued access to the platform for authorized employees across all FDA divisions. Predicting DILi risk supports informed decision-making regarding drug evaluations and approvals. Simulations Plus, Inc.
Benzinga · 04/04 12:35
Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Flora Growth Corp. Fell sharply in today's pre-market trading. The company reported the launch of a proposed public offering of common shares. Levi Strauss & Co. Shares rose 7.9% on Wednesday after the company reported upbeat earnings for its first quarter. HWH International Inc. And VivoPower surged 175% and 14.5% in pre- market trading.
Benzinga · 04/04 11:58
Simulations Plus (SLP) Q2 Earnings & Revenues Beat Estimates
NASDAQ · 04/04 10:34
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
Shares of Simulations Plus, Inc. Rose sharply in today’s pre-market trading after the company posted better-than-expected results for its second quarter. The Dow futures were higher by around 90 points on Thursday morning. Destiny Tech100 Inc. And Cronos Group also recorded gains in today's pre- market trading.
Benzinga · 04/04 09:18
Levi Strauss, Conagra Brands And 3 Stocks To Watch Heading Into Thursday
Wall Street expects Conagra Brands, Inc. To report quarterly earnings at 65 cents per share before the opening bell. Levi Strauss & Co. Reported upbeat earnings for its first quarter and boosted its 2024 earnings guidance. Simulations Plus posted better-than-expected results for its second quarter.
Benzinga · 04/04 05:53
SLP Stock Earnings: Simulations Plus Beats EPS, Beats Revenue for Q2 2024
Simulations Plus reported earnings per share of 20 cents for the second quarter of 2024. The company reported revenue of $18.31 million. This was 5.93% better than the analyst estimate for revenue. Simulations Plus also reported results for the first quarter of 2019.
Investorplace · 04/04 00:53
Stocks to Watch: Levi Strauss, BlackBerry, Simulations Plus
Levi Strauss slightly increased its full-year guidance for adjusted earnings per share. BlackBerry posted an adjusted profit ahead of Wall Street's estimates. Simulations Plus's revenue rose 16% in the fiscal second quarter. Shares rose 7.7% to $41.43 after-hours.
Dow Jones · 04/03 23:28
Simulations Plus Shares Climb 7% After 2Q Revenue Beat
Shares of Simulations Plus climbed 7.3% to $41.25 in post-market trading on Wednesday. The company posted better-than-expected results for its fiscal second quarter. The provider of modeling and simulation software and services for pharmaceutical safety and efficacy reported a net profit.
Dow Jones · 04/03 22:01
More
Webull provides a variety of real-time SLP stock news. You can receive the latest news about Simulations Plus Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLP
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.